| pubmed-article:11598844 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11598844 | lifeskim:mentions | umls-concept:C0021051 | lld:lifeskim |
| pubmed-article:11598844 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:11598844 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:11598844 | lifeskim:mentions | umls-concept:C0039736 | lld:lifeskim |
| pubmed-article:11598844 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11598844 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:11598844 | pubmed:dateCreated | 2001-10-12 | lld:pubmed |
| pubmed-article:11598844 | pubmed:abstractText | The safety and immune effects of low-dose thalidomide treatment (3 mg/kg/day for 28 days) were evaluated in a study involving 8 South African human immunodeficiency virus (HIV)-infected children. The children were 7-69 months old and in disease stages A1-C3. Thalidomide therapy did not affect virus load, even though none of the children was receiving antiretroviral therapy. Thalidomide stimulated CD8+ T cells in peripheral blood, which increased expression of the activation markers CD38 and human leukocyte antigen DR and of the memory cell marker CD45RO. The frequency of HIV gag-specific CD8+ T cells in peripheral blood increased in 3 of 4 children who were evaluated during treatment with thalidomide. Clinical adverse events were mild. In this study, thalidomide was found to be safe and well tolerated and caused significant immunomodulation at a low dose. This is the first report describing use of an oral drug that may enhance HIV-specific CD8+ T cell function in HIV-infected children. | lld:pubmed |
| pubmed-article:11598844 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11598844 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11598844 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11598844 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11598844 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11598844 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11598844 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11598844 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11598844 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:HughesJJ | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:KaplanGG | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:AllinRR | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:HusseyG DGD | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:GoddardEE | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:HaslettP APA | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:HanekomW AWA | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:ApollesPP | lld:pubmed |
| pubmed-article:11598844 | pubmed:author | pubmed-author:GanisoVV | lld:pubmed |
| pubmed-article:11598844 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11598844 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11598844 | pubmed:volume | 184 | lld:pubmed |
| pubmed-article:11598844 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11598844 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11598844 | pubmed:pagination | 1192-6 | lld:pubmed |
| pubmed-article:11598844 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:meshHeading | pubmed-meshheading:11598844... | lld:pubmed |
| pubmed-article:11598844 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11598844 | pubmed:articleTitle | The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children. | lld:pubmed |
| pubmed-article:11598844 | pubmed:affiliation | Laboratory of Cellular Physiology and Immunology, The Rockefeller University, 1230 York Ave., New York, NY 10021, USA. hanekow@rockefeller.edu | lld:pubmed |
| pubmed-article:11598844 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11598844 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11598844 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11598844 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
